Regulation of vascular endothelial growth factor synthesis by nitric oxide: Facts and controversies

Antioxidants and Redox Signaling

Volumn 5, Issue 1, 2003, Pages 123-132

  Dulak, Józef ^a   Józkowicz, Alicja ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; ENZYME ACTIVATION; HORMONAL REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

EID: 0037297175     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/152308603321223612     Document Type: Review

References (90)

1. Adhikary G, Premkumar DR, and Prabhakar NR. Dual influence of nitric oxide on gene regulation during hypoxia. Adv Exp Med Biol 475: 285-292, 2000.
2. Agani FH, Puchowicz M, Chavez JC, Pichiule P, and LaManna J. Role of nitric oxide in the regulation of HIF-1 alpha expression during hypoxia. Am J Physiol Cell Physiol 283: C178-C186, 2002.
3. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, and Harris CC. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 4: 1371-1376, 1998.
4. Ankoma-Sey V, Wang Y, and Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31: 141-148, 2000.
5. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, and Livingston DM. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 93: 12969-1273, 1996.
6. Bauer PM, Buga GM, and Ignarro LJ. Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci U S A 98: 12802-12807, 2001.
7. Beerepoot LV, Shima DT, Kuroki M, Yeo KT, and Voest EE. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res 56: 3747-3751, 1996.
8. Benoit H, Jordan M, Wagner H, and Wagner PD. Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression. J Appl Physiol 86: 1513-1518, 1999.
9. Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, and Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 60: 1171-1178, 2000.
10. Bhalla US and Iyengar R. Emergent properties of networks of biological signaling pathways. Science 283: 381-387, 1999.
11. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, and Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273: 11995-11998, 1998.
12. Brune B, von Knethen A, and Sandau KB. Transcription factors p53 and HIF-1alpha as targets of nitric oxide. Cell Signal 13: 525-533, 2001.
13. Cao M, Westerhausen-Larson A, Niyibizi C, Kavalkovich K, Georgescu HI, Rizzo CF, Hebda PA, Stefanovic-Racic M, and Evans CH. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J 324 (Pt 1): 305-310, 1997.
14. Chin K, Kurashima Y, Ogura T, Tajiri H, Yoshida S, and Esumi H. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 15: 437-442, 1997.
15. Cooke JP and Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.
16. Da Silva-Azevedo L, Baum O, Zakrzewicz A, and Pries A. Vascular endothelial growth factor is expressed in endothelial cells isolated from skeletal muscles of nitric oxide synthase knockout mice during prazosin-induced angiogenesis. Biochem Biophys Res Commun 297: 1270-1276, 2002.
17. Dulak J. New mechanisms of regulation of vascular endothelial growth factor synthesis. The role of nitric oxide and carbon monoxide. (Thesis) Institute of Molecular Biology, Jagiellonian University, Krakow, 2001, p.76.
18. Dulak J and Jozkowicz A. Nitric oxide in vascular endothelial growth factor synthesis and signaling. Circulation 104: E48-E49, 2001
19. Dulak J, Polus M, Guevara I, Polus A, Hartwich J, and Dembinska-Kiec A. Regulation of inducible nitric oxide synthase (iNOS) and GTP cyclohydrolase I (GTP-CH I) gene expression by ox-LDL in rat vascular smooth muscle cells. J Physiol Pharmacol 48: 689-697, 1997.
20. Dulak J, Jozkowicz A, Guevara I, and Dembinska-Kiec A. Gene transfer of vascular endothelial growth factor and endothelial nitric oxide synthase - implications for gene therapy in cardiovascular diseases. Pol J Pharmacol 51: 233-241, 1999.
21. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wojtowicz A, Szuba A, and Cooke JP. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 659-666, 2000.
22. Dulak J, Jozkowicz A, Dichtl W, Alber H, Schwarzacher SP, Pachinger O, and Weidinger F. VEGF synthesis in vascular smooth muscle cells is enhanced by 7-ketocholesterol and lysophosphatidylcholine independently of their effect on nitric oxide generation. Atherosclerosis 159: 325-332, 2001.
23. Dulak J, Motterlini R, Huk I, Pachinger O, Weidinger F, and Józkowicz A. Carbon monoxide and iron, by-products of heme oxygenase, modulate vascular endothelial growth factor synthesis in vascular smooth muscle cells. In: Heme Oxygenase in Biology and Medicine, edited by Abraham NG, Alam J and Nath K. New York, NY: Kluwer Academic/Plenum Publisher, 2002, pp. 97-107.
24. Dulak J, Jozkowicz A, Foresti R, Kasza A, Frick M, Huk I, Green CJ, Pachinger O, Weidinger F, and Motterlini R. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid Redox Signal 4: 229-240, 2002.
25. Dulak J, Motterlini R, and Jozkowicz A. Mechanisms of nitric oxide-mediated induction of vascular endothelial growth factor synthesis (Abstract). Nitric Oxide 6: 4, 2002.
26. Foresti R and Motterlini R. The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. Free Radic Res 31: 459-475, 1999
27. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
28. Frank S, Madlener M, Pfeilschifter J, and Werner S. induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin-cofactor-synthesizing enzyme GTP-cyclohydrolase I during cutaneous wound repair. J Invest Dermatol 111: 1058-1064, 1998.
29. Frank S, Stallmeyer B, Kampfer H, Kolb N, and Pfeilschifter J. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J 13: 2002-2014, 1999.
30. Frank S, Stallmeyer B, Kampfer H, Schaffner C, and Pfeilschifter J. Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. Biochem J338 (Pt 2): 367-374, 1999.
31. Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, and Yamauchi-Takihara K. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 275: 10561-10566, 2000.
32. Gavin TP, Spector DA, Wagner H, Breen EC, and Wagner PD. Nitric oxide synthase inhibition attenuates the skeletal muscle VEGF mRNA response to exercise. J Appl Physiol 88: 1192-1198, 2000.
33. Genius J and Fandrey J. Nitric oxide affects the production of reactive oxygen species in hepatoma cells: implications for the process of oxygen sensing. Free Radic Biol Med 29: 515-521, 2000.
34. Ghiso N, Rohan RM, Amano S, Garland R, and Adamis AP. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci 40: 1033-1039, 1999.
35. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996.
36. Huang LE, Willmore WG, Gu J, Goldberg MA, and Bunn HF. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 274: 9038-9044, 1999.
37. Ioannidis I, Batz M, Paul T, Korth HG, Sustmann R, and De Groot H. Enhanced release of nitric oxide causes increased cytotoxicity of S-nitroso-N-acetyl-DL-penicillamine and sodium nitroprusside under hypoxic conditions. Biochem J 318 (Pt 3): 789-795, 1996.
38. 2 sensing. Science 292: 464-468, 2001.
39. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
40. Jadeski LC, Hum KO, Chakraborty C, and Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86: 30-39, 2000.
41. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, and Moncada S. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 70: 847-859, 1994.
42. Jover B and Mimran A. Nitric oxide inhibition and renal alterations. J Cardiovasc Pharmacol 38 (Suppl 2): S65-S70, 2001.
43. Jozkowicz A, Cooke JP, Guevara I, Huk I, Funovics P, Pachinger O, Weidinger F, and Dulak J. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res 51: 773-783, 2001.
44. Jozkowicz A, Huk I, Nigisch A, Weigel G, Weidinger F, and Dulak J: Effect of prostaglandin-J2 on VEGF synthesis depends on the induction of heme oxygenase-1 Antioxid Redox Signal 4: 577-585, 2002
45. Kane AJ, Barker JE, Mitchell GM, Theile DR, Romero R, Messina A, Wagh M, Fraulin FO, Morrison WA, and Stewart AG. Inducible nitric oxide synthase (iNOS) activity promotes ischaemic skin flap survival. Br J Pharmacol 132: 1631-1638, 2001.
46. Kang DH, Nakagawa T, Feng L, and Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002.
47. Kibbe MR, Li J, Nie S, Choi BM, Kovesdi I, Lizonova A, Billiar TR, and Tzeng E. Potentiation of nitric oxide-induced apoptosis in p53-/- vascular smooth muscle cells. Am J Physiol Cell Physiol 282: C625-C634, 2002.
48. Kim S and Ponka P. Control of transferrin receptor expression via nitric oxide-mediated modulation of ironregulatory protein 2. J Biol Chem 274: 33035-33042, 1999.
49. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, Addeo R, Makuuchi M, and Esumi H. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95: 189-197, 2000.
50. Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Acquisto F, Makuuchi M, and Esumi H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 276: 2292-2298, 2001.
51. Kimura H, Ogura T, Kurashima Y, Weisz A, and Esumi H. Effects of nitric oxide donors on vascular endothelial growth factor gene induction. Biochem Biophys Res Commun 296: 976-982, 2002
52. Konopka TE, Barker JE, Bamford TL, Guida E, Anderson RL, and Stewart AG. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 61: 3182-3187, 2001.
53. Kreiser D, Nguyen X, Wong R, Seidman D, Stevenson D, Quan S, Abraham N, and Dennery PA. Heme oxygenase-1 modulates fetal growth in the rat. Lab Invest 82: 687-692, 2002.
54. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, and Adamis AP. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98: 1667-1675, 1996.
55. Lala PK and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2: 149-156, 2001.
56. Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861, 2002.
57. 2A receptor agonists and endotoxin. Am J Pathol 160: 2231-2244, 2002.
58. Liu Y, Christou H, Morita T, Laughner E, Semenza GL, and Kourembanas S. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer. J Biol Chem 273: 15257-15262, 1998.
59. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554, 1997.
60. Marshall HE, Merchant K, and Stamler JS. Nitrosation and oxidation in the regulation of gene expression. FASEB J 14: 1889-1900, 2000.
61. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, and Chilian WM. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 102: 3098-3103, 2000.
62. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
63. Minchenko A, Bauer T, Salceda S, and Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71: 374-379, 1994.
64. Minchenko A, Salceda S, Bauer T, and Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40: 35-39, 1994.
65. Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, and Green CJ. Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. J Biol Chem 275: 13613-13620, 2000.
66. Neufeld G, Cohen T, Gengrinovitch S, and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
67. Palmer L, Steinke KB, and Gaston B. S-Nitrosylation of Von Hippel-Lindau protein: implications for hypoxia inducible factor-1 regulation (Abstract). Nitric Oxide 6: 4, 2002.
68. Palmer LA, Gaston B, and Johns RA. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Mol Pharmacol 58: 1197-1203, 2000.
69. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44, 2000.
70. Richard DE, Berra E, Gothie E, Roux D, and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637, 1999.
71. Richardson DR and Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331: 1-40, 1997.
72. Sandau KB, Faus HG, and Brune B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 278: 263-267, 2000.
73. Sandau KB, Fandrey J, and Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 97: 1009-1015, 2001.
74. Sandau KB, Zhou J, Kietzmann T, and Brune B. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 276: 39805-398011, 2001.
75. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7: 345-350, 2001.
76. Sennlaub F, Courtois Y, and Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 107: 717-725, 2001.
77. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, and Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 93: 13176-13181, 1996.
78. Sogawa K, Numayama-Tsuruta K, Ema M, Abe M, Abe H, and Fujii-Kuriyama Y. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc Natl Acad Sci U S A 95: 7368-7373, 1998.
79. Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J, and Frank S. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol 113: 1090-1098, 1999.
80. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, and Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
81. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, and Isner JM. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 3: 879-886, 1997.
82. Tuder RM, Flook BE, and Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95: 1798-1807, 1995.
83. Turpaev K, Litvinov D, Dubovaya V, Panasyuk A, Ivanov D, and Prassolov V. Induction of vascular endothelial growth factor by nitric oxide in cultured human articular chondrocytes. Biochimie 83: 515-522, 2001.
84. Watts RN and Richardson DR. Nitrogen monoxide (NO) and glucose: unexpected links between energy metabolism and NO-mediated iron mobilization from cells. J Biol Chem 276: 4724-4732, 2001.
85. Williams B, Baker AQ, Gallacher B, and Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25: 913-917, 1995.
86. Xiong M, Elson G, Legarda D, and Leibovich SJ. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 153: 587-598, 1998.
87. Yin JH, Yang DI, Ku G, and Hsu CY. iNOS expression inhibits hypoxia-inducible factor-1 activity. Biochem Biophys Res Commun 279: 30-34, 2000.
88. Yla-Herttuala S and Martin JF. Cardiovascular gene therapy. Lancet 355: 213-222, 2000.
89. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280: C1375-C1386, 2001.
90. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa Ki K, Ichiki T, Shibuya M, and Takeshita A. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105: 1110-1115, 2002.